These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 25975129)

  • 21. Magnetic resonance imaging of malignant lymphoma.
    Vermoolen MA; Kersten MJ; Fijnheer R; van Leeuwen MS; Kwee TC; Nievelstein RA
    Expert Rev Hematol; 2011 Apr; 4(2):161-71. PubMed ID: 21495926
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Whole-body MRI, including diffusion-weighted imaging, for the initial staging of malignant lymphoma: comparison to computed tomography.
    Kwee TC; van Ufford HM; Beek FJ; Takahara T; Uiterwaal CS; Bierings MB; Ludwig I; Fijnheer R; Nievelstein RA
    Invest Radiol; 2009 Oct; 44(10):683-90. PubMed ID: 19724232
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PET/MRI: challenges, solutions and perspectives.
    Herzog H
    Z Med Phys; 2012 Dec; 22(4):281-98. PubMed ID: 22925652
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preoperative mediastinal and hilar nodal staging with diffusion-weighted magnetic resonance imaging and fluorodeoxyglucose positron emission tomography/computed tomography in patients with non-small-cell lung cancer: which is better?
    Wu LM; Xu JR; Gu HY; Hua J; Chen J; Zhang W; Haacke EM; Hu J
    J Surg Res; 2012 Nov; 178(1):304-14. PubMed ID: 22541065
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nodal staging of rectal cancer: high-resolution pelvic MRI versus ¹⁸F-FDGPET/CT.
    Kim DJ; Kim JH; Ryu YH; Jeon TJ; Yu JS; Chung JJ
    J Comput Assist Tomogr; 2011; 35(5):531-4. PubMed ID: 21926843
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of whole-body PET/CT and PET/MRI in breast cancer patients: lesion detection and quantitation of 18F-deoxyglucose uptake in lesions and in normal organ tissues.
    Pace L; Nicolai E; Luongo A; Aiello M; Catalano OA; Soricelli A; Salvatore M
    Eur J Radiol; 2014 Feb; 83(2):289-96. PubMed ID: 24331845
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnostic value of whole-body diffusion-weighted magnetic resonance imaging for detection of primary and metastatic malignancies: a meta-analysis.
    Li B; Li Q; Nie W; Liu S
    Eur J Radiol; 2014 Feb; 83(2):338-44. PubMed ID: 24355655
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Value of fusion of PET and MRI for staging of endometrial cancer: comparison with ¹⁸F-FDG contrast-enhanced PET/CT and dynamic contrast-enhanced pelvic MRI.
    Kitajima K; Suenaga Y; Ueno Y; Kanda T; Maeda T; Takahashi S; Ebina Y; Miyahara Y; Yamada H; Sugimura K
    Eur J Radiol; 2013 Oct; 82(10):1672-6. PubMed ID: 23727380
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FDG-PET imaging for Hodgkin lymphoma: current use and future applications.
    Kostakoglu L; Evens AM
    Clin Adv Hematol Oncol; 2014 Jan; 12(1):20-35. PubMed ID: 25000313
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Depiction and characterization of liver lesions in whole body [¹⁸F]-FDG PET/MRI.
    Beiderwellen K; Gomez B; Buchbender C; Hartung V; Poeppel TD; Nensa F; Kuehl H; Bockisch A; Lauenstein TC
    Eur J Radiol; 2013 Nov; 82(11):e669-75. PubMed ID: 24011443
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diffusion-weighted MR imaging in comparison to integrated [¹⁸F]-FDG PET/CT for N-staging in patients with lung cancer.
    Pauls S; Schmidt SA; Juchems MS; Klass O; Luster M; Reske SN; Brambs HJ; Feuerlein S
    Eur J Radiol; 2012 Jan; 81(1):178-82. PubMed ID: 20932700
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of the accuracy of PET/CT and PET/MRI spatial registration of multiple metastatic lesions.
    Rakheja R; DeMello L; Chandarana H; Glielmi C; Geppert C; Faul D; Friedman KP
    AJR Am J Roentgenol; 2013 Nov; 201(5):1120-3. PubMed ID: 24147486
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of PET-CT and magnetic resonance diffusion weighted imaging with body suppression (DWIBS) for initial staging of malignant lymphomas.
    Stéphane V; Samuel B; Vincent D; Joelle G; Remy P; Francois GG; Jean-Pierre T
    Eur J Radiol; 2013 Nov; 82(11):2011-7. PubMed ID: 23932096
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Whole-Body Diffusion-weighted Imaging in Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma.
    Toledano-Massiah S; Luciani A; Itti E; Zerbib P; Vignaud A; Belhadj K; Baranes L; Haioun C; Lin C; Rahmouni A
    Radiographics; 2015; 35(3):747-64. PubMed ID: 25815803
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnosis of peritoneal dissemination: comparison of 18F-FDG PET/CT, diffusion-weighted MRI, and contrast-enhanced MDCT.
    Satoh Y; Ichikawa T; Motosugi U; Kimura K; Sou H; Sano K; Araki T
    AJR Am J Roentgenol; 2011 Feb; 196(2):447-53. PubMed ID: 21257899
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Non-small cell lung cancer staging: efficacy comparison of integrated PET/CT versus 3.0-T whole-body MR imaging.
    Yi CA; Shin KM; Lee KS; Kim BT; Kim H; Kwon OJ; Choi JY; Chung MJ
    Radiology; 2008 Aug; 248(2):632-42. PubMed ID: 18552311
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimized contrast-enhanced CT protocols for diagnostic whole-body 18F-FDG PET/CT: technical aspects of single-phase versus multiphase CT imaging.
    Brechtel K; Klein M; Vogel M; Mueller M; Aschoff P; Beyer T; Eschmann SM; Bares R; Claussen CD; Pfannenberg AC
    J Nucl Med; 2006 Mar; 47(3):470-6. PubMed ID: 16513616
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FDG-PET response-adapted therapy: is 18F-fluorodeoxyglucose positron emission tomography a safe predictor for a change of therapy?
    Hutchings M
    Hematol Oncol Clin North Am; 2014 Feb; 28(1):87-103. PubMed ID: 24287070
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of combined DWIBS/3D-CE-T1w whole-body MRI in tumor staging: Comparison with PET-CT.
    Manenti G; Cicciò C; Squillaci E; Strigari L; Calabria F; Danieli R; Schillaci O; Simonetti G
    Eur J Radiol; 2012 Aug; 81(8):1917-25. PubMed ID: 21908120
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Non-small cell lung cancer: whole-body MR examination for M-stage assessment--utility for whole-body diffusion-weighted imaging compared with integrated FDG PET/CT.
    Ohno Y; Koyama H; Onishi Y; Takenaka D; Nogami M; Yoshikawa T; Matsumoto S; Kotani Y; Sugimura K
    Radiology; 2008 Aug; 248(2):643-54. PubMed ID: 18539889
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.